Urinary biomarkers for hepatocellular carcinoma: current knowledge for clinicians

Cancer Cell International

Review

Gang Xu¹  Kaige Deng²  Xueshuai Wan²  Shunda Du²  Yongchang Zheng²  Bao Jin²  Jiali Xing²  Xinting Sang² 

[1] Department of Liver Surgery and Liver Transplant Center, West China Hospital of Sichuan University, Chengdu, China;Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, 1 Shuaifuyuan, Dongcheng District, 100730, Beijing, China;

关键词: Hepatocellular carcinoma;    Urine testing;    Biomarkers;    Diagnosis;    Prognosis;    Multi-omics;   

DOI  :  10.1186/s12935-023-03092-5

 received in 2023-05-29, accepted in 2023-10-04,  发布年份 2023

来源: Springer

【 摘 要 】

Hepatocellular carcinoma (HCC) is the most predominant primary liver cancer, causing many illnesses and deaths worldwide. The insidious clinical presentation, difficulty in early diagnosis, and the highly malignant nature make the prognosis of HCC extremely poor. The complex and heterogeneous pathogenesis of HCC poses significant challenges to developing therapies. Urine-based biomarkers for HCC, including diagnostic, prognostic, and monitoring markers, may be valuable supplements to current tools such as serum α-fetoprotein (AFP) and seem promising for progress in precision medicine. Herein, we reviewed the major urinary biomarkers for HCC and assessed their potential for clinical application. Molecular types, testing platforms, and methods for building multimolecule models in the included studies have shown great diversity, thus providing abundant novel tools for future clinical transformation and applications.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 2

12951_2016_246_Article_IEq16.gif

12951_2016_246_Article_IEq13.gif

Fig. 2

12936_2017_1904_Article_IEq1.gif